Qualigen Therapeutics (QLGN) announced that it received an expected deficiency notification letter from Nasdaq on April 24. The notice indicated that the company was not in compliance with Nasdaq Listing Rule 5250 as a result of its failure to timely file its Annual Report on Form 10-K for the annual period ended December 31, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QLGN: